ATEL Ventures has completed an agreement to provide $10M of growth capital to Vial, a next-generation pharma company.
Founded in 2020 and headquartered in San Francisco, California, Vial is a clinical-stage biotech company based in San Francisco that has raised $100M+ to date from leading life sciences investors including General Catalyst, Buckley Ventures, and Byers Capital. Vial is focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet medical need.
Vial recently initiated dosing of healthy volunteers in its first clinical trial for a novel subcutaneous, extended half-life monoclonal antibody targeting TL1A, which is being developed as a potentially best-in-class treatment for people living with moderate-to-severe IBD, as well as other I&I and fibrotic diseases. The $10M from ATEL Ventures will complement Vial’s historical equity financings and enable the Vial team to advance additional assets into the clinic in 2025, leveraging its vertically integrated drug development, clinical trial technology, and clinical operations platform.
“Drug development and clinical trials have always been slow-moving and capital-intensive,” said Steven Rea, President, ATEL Ventures. “Vial’s platform turns all of that on its head, streamlining the process and enabling new drugs to get to market that much faster.”
“We are reimagining drug development, using technology to build for scale,” said Simon Burns, CEO of Vial. The financing from ATEL complements our historical equity funding and supports our ability to accelerate the number of clinical stage assets in our pipeline.